2-Pyrocatechuic acid



Compound IDCDAMM00401
Common name2-Pyrocatechuic acid
IUPAC name2,3-dihydroxybenzoic acid
Molecular formulaC7H6O4

Experimental data

Retention time17.215
Adduct[M+H]+
Actual mz155.035
Theoretical mz155.034
Error3.96
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.59

Identifiers and class information

Inchi keyGLDQAMYCGOIJDV-UHFFFAOYSA-N 
SmilesC1=CC(=C(C(=C1)O)O)C(=O)O
SuperclassBenzenoids
ClassBenzene and substituted derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)3
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)154.122
Computed dipole moment(dipole)8.226
Total solvent accessible surface area (SASA)326.026
Hydrophobic component of SASA (FOSA)0
Hydrophilic component of SASA (FISA)188.73
Pie component of the SASA (PISA)137.296
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)499.918
Number of hydrogen bond donors (donorHB)2
Number of hydrogen bond acceptors (accptHB)2.5
Free energy of solvation of dipole (dip^2/V)0.135358
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0108443
Globularity descriptor (glob)0.934354
Predicted polarizability in cubic angstroms (QPpolrz)13.238
Predicted hexadecane/gas partition coefficient (QPlogPC16)5.779
Predicted octanol/gas partition coefficient (QPlogPoct)10.255
Predicted water/gas partition coefficient (QPlogPw)7.451
Predicted octanol/water partition coefficient (QPlogPo/w)0.853
Predicted aqueous solubility (QPlogS)-1.027
Conformation-independent predicted aqueous solubility (CIQPlogS)-1.697
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-1.441
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)40.717
Predicted brain/blood partition coefficient (QPlogBB)-1.059
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)19.775
Predicted skin permeability, log Kp (QPlogKp)-4.226
PM3 calculated ionization potential (IP(ev))9.502
PM3 calculated electron affinity (EA(eV))0.667
Number of likely metabolic reactions (#metab)2
Prediction of binding to human serum albumin (QPlogKhsa)-0.787
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)60.754
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)90.505
Number of nitrogen and oxygen atoms (#NandO)4
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
Q07820MCL1Induced myeloid leukemia cell differentiation protein Mcl-1T14912SEA
Q8TDS4HCAR2Hydroxycarboxylic acid receptor 2T88185SEA
P00915CA1Carbonic anhydrase IT13201SEA
P02766TTRTransthyretinT86462SEA
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P39086GRIK1Glutamate receptor ionotropic kainate 1T73495SEA
P23141CES1Acyl coenzyme A:cholesterol acyltransferaseT76369SEA
P42330AKR1C3Aldo-keto-reductase family 1 member C3T60857SEA
Q6B0I6KDM4DLysine-specific demethylase 4DT17036SEA
O75164KDM4ALysine-specific demethylase 4AT18904SEA
Q6B0I6KDM4DLysine-specific demethylase 4DT17036SEA
P29350PTPN6Protein-tyrosine phosphatase 1CT98264SEA
P15090FABP4Fatty acid binding protein adipocyteT07217SEA
Q9Y4C1KDM3ALysine-specific demethylase 3AT25362SEA
P27695APEX1DNA-(apurinic or apyrimidinic site) lyaseT13348SEA
P24723PRKCHProtein kinase C etaT40149SEA
P08263GSTA1Glutathione S-transferase A1T17221SEA
Q99523SORT1Neurotensin receptor 3T63233SEA
Q02127DHODHDihydroorotate dehydrogenaseT61400SEA
P17936IGFBP3Insulin-like growth factor binding protein 3T33455SEA
Q12791KCNMA1Calcium-activated potassium channel subunit alpha-1T66538SEA
Q9NPH5NOX4NADPH oxidase 4T29741SEA
P05129PRKCGProtein kinase C gammaT47107SEA
P22736NR4A1Nuclear receptor subfamily 4 group A member 1T41119SEA
Q96RR4CAMKK2CaM-kinase kinase betaT82262SEA
Q15109AGERAdvanced glycosylation end product receptorT07400SEA
Q04609FOLH1Glutamate carboxypeptidase IIT97071SEA
P09172DBHDopamine beta hydroxylaseT74937SEA
Q7RTX1TAS1R1Taste receptorT41263SEA
P46952HAAO3-hydroxyanthranilate oxygenaseT46527SEA
Q9NXA8SIRT5NAD-dependent deacetylase sirtuin-5T91940SEA
Q07108CD69Early activation antigen CD69T48780SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T14912DI0012Acute myeloid leukaemia[ICD-11: 2A60]Q07820MCL1
T14912DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]Q07820MCL1
T14912DI0250Mature B-cell lymphoma[ICD-11: 2A85]Q07820MCL1
T14912DI0252Melanoma[ICD-11: 2C30]Q07820MCL1
T14912DI0274Multiple myeloma[ICD-11: 2A83]Q07820MCL1
T14912DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q07820MCL1
T88185DI0203Inborn lipid metabolism error[ICD-11: 5C52]Q8TDS4HCAR2
T13201DI0166Glaucoma[ICD-11: 9C61]P00915CA1
T13201DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00915CA1
T86462DI0026Amyloidosis[ICD-11: 5D00]P02766TTR
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T73495DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P39086GRIK1
T73495DI0396Substance abuse[ICD-11: 6C40]P39086GRIK1
T76369DI0335Peroxisomal disease[ICD-11: 5C57]P23141CES1
T76369DI0398Synthesis disorder[ICD-11: 5C52-5C59]P23141CES1
T60857DI0145Female pelvic pain[ICD-11: GA34]P42330AKR1C3
T13348DI0365Retinopathy[ICD-11: 9B71]P27695APEX1
T13348DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P27695APEX1
T40149DI0184Human immunodeficiency virus disease[ICD-11: 1C60-1C62]P24723PRKCH
T63233DI0153Frontotemporal dementia[ICD-11: 6D83]Q99523SORT1
T61400DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]Q02127DHODH
T61400DI0275Multiple sclerosis[ICD-11: 8A40]Q02127DHODH
T33455DI0115Dementia[ICD-11: 6D80-6D8Z]P17936IGFBP3
T66538DI0037Asthma[ICD-11: CA23]Q12791KCNMA1
T66538DI0154Functional bladder disorder[ICD-11: GC50]Q12791KCNMA1
T29741DI0146Fibrosis[ICD-11: GA14-GC01]Q9NPH5NOX4
T47107DI0012Acute myeloid leukaemia[ICD-11: 2A60]P05129PRKCG
T47107DI0248Mastocytosis[ICD-11: 2A21]P05129PRKCG
T07400DI0025Alzheimer disease[ICD-11: 8A20]Q15109AGER
T07400DI0083Chronic kidney disease[ICD-11: GB61]Q15109AGER
T07400DI0115Dementia[ICD-11: 6D80-6D8Z]Q15109AGER
T07400DI0196Hypotension[ICD-11: BA20-BA21]Q15109AGER
T97071DI0122Diagnostic imaging[ICD-11: N.A.]Q04609FOLH1
T97071DI0346Prostate cancer[ICD-11: 2C82]Q04609FOLH1
T74937DI0175Heart failure[ICD-11: BD10-BD1Z]P09172DBH
T74937DI0341Post-traumatic stress disorder[ICD-11: 6B40]P09172DBH
T41263DI0078Cholera[ICD-11: 1A00]Q7RTX1TAS1R1

Copyright © 2025